Imagion Biosystems has achieved a key milestone in its progress to first-in-human testing with the successful completion of a toxicology safety study of its lead MagSense® nanoparticle formulation for the detection of HER2 metastatic breast cancer.
Read the announcement.
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session